Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G10 | O15496 | 2/20 | 0.55 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.55 |
| ▸ | TLR2 | O60603 | 8/20 | 0.49 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.49 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.49 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.49 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.48 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.48 |
| ▸ | CETP | P11597 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3762356 | 1.00 | PLA2G10 (0.55) | PLA2G10PLA2G2ATLR2LPAR1LPAR3 | |
| SCHEMBL31514669 | 1.00 | PLA2G10 (0.55) | PLA2G10PLA2G2ATLR2LPAR1LPAR3 | |
| SCHEMBL6811774 | 1.00 | PLA2G10 (0.55) | PLA2G10PLA2G2ATLR2LPAR1LPAR3 | |
| SCHEMBL25078776 | 1.00 | PLA2G10 (0.55) | PLA2G10PLA2G2ATLR2LPAR1LPAR3 | |
| SCHEMBL13997509 | 1.00 | PLA2G10 (0.55) | PLA2G10PLA2G2ATLR2LPAR1LPAR3 | |
| SCHEMBL25078765 | 1.00 | PLA2G10 (0.55) | PLA2G10PLA2G2ATLR2LPAR1LPAR3 | |
| SCHEMBL6813208 | 1.00 | PLA2G10 (0.55) | PLA2G10PLA2G2ATLR2LPAR1LPAR3 | |
| SCHEMBL4368865 | 1.00 | PLA2G10 (0.55) | PLA2G10PLA2G2ATLR2LPAR1LPAR3 | |
| SCHEMBL2411920 | 1.00 | PLA2G10 (0.55) | PLA2G10PLA2G2ATLR2LPAR1LPAR3 | |
| SCHEMBL31514666 | 1.00 | PLA2G10 (0.55) | PLA2G10PLA2G2ATLR2LPAR1LPAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9365506-B2 | Compounds and compositions as TLR2 agonists | NOVARTIS AG (CH) | 2016-06-14 | — | — | US | disclosed |
| US-20140323390-A1 | COMPOUNDS AND COMPOSITIONS AS TLR2 AGONISTS | IRM LLC (BM) | 2014-10-30 | — | — | US | disclosed |
| US-8808703-B2 | Compounds (cystein based lipopeptides) and compositions as TLR2 agonists used for treating infections, inflammations, respiratory diseases etc | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2014-08-19 | — | — | US | disclosed |
| US-20130065861-A1 | COMPOUNDS (CYSTEIN BASED LIPOPEPTIDES) AND COMPOSITIONS AS TLR2 AGONISTS USED FOR TREATING INFECTIONS, INFLAMMATIONS, RESPIRATORY DISEASES ETC. | IRM LLC (BM) | 2013-03-14 | — | — | US | disclosed |
| EP-2549990-A1 | COMPOUNDS (CYSTEIN BASED LIPOPEPTIDES) AND COMPOSITIONS AS TLR2 AGONISTS USED FOR TREATING INFECTIONS, INFLAMMATIONS, RESPIRATORY DISEASES ETC. | IRM LLC (BM) | 2013-01-30 | — | — | EP | disclosed |
| WO-2011119759-A1 | COMPOUNDS (CYSTEIN BASED LIPOPEPTIDES) AND COMPOSITIONS AS TLR2 AGONISTS USED FOR TREATING INFECTIONS, INFLAMMATIONS, RESPIRATORY DISEASES ETC. | IRM LLC (BM) | 2011-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323390-A1 | COMPOUNDS AND COMPOSITIONS AS TLR2 AGONISTS | TLR2, TLR1, TLR3 | PLA2G10 302/4885PLA2G2A 211/4885TLR2 1/4885 |
| US-20130065861-A1 | COMPOUNDS (CYSTEIN BASED LIPOPEPTIDES) AND COMPOSITIONS AS TLR2 AGONISTS USED FOR TREATING INFECTIONS, INFLAMMATIONS, RESPIRATORY DISEASES ETC. | TLR2, TLR4, TLR3 | PLA2G10 377/4885PLA2G2A 393/4885TLR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.